BerGenBio Gestion

Gestion contrôle des critères 2/4

Le PDG BerGenBio's est Martin Olin, nommé en Sep2021, a un mandat de 3.08 ans. La rémunération annuelle totale est NOK 10.23M, composée du salaire de 51.5% et des bonus 48.5%, y compris les actions et options de la société. détient directement 0.078% des actions de la société, d'une valeur de NOK 307.05K. La durée moyenne de mandat de l'équipe de direction et du conseil d'administration est respectivement 3 ans et 1.7 ans.

Informations clés

Martin Olin

Directeur général

NOK 10.2m

Rémunération totale

Pourcentage du salaire du PDG	51.5%
Durée du mandat du directeur général	3.1yrs
Propriété du PDG	0.08%
Durée moyenne d'occupation des postes de direction	3yrs
Durée moyenne du mandat des membres du conseil d'administration	1.7yrs

Mises à jour récentes de la gestion

Recent updates

Analyse de la rémunération des PDG

Comment la rémunération de Martin Olin a-t-elle évolué par rapport aux bénéfices de BerGenBio?
Date	Rémunération totale	Salaire	Bénéfices de l'entreprise
Jun 30 2024	n/a	n/a	-NOK 155m
Mar 31 2024	n/a	n/a	-NOK 155m
Dec 31 2023	NOK 10m	NOK 5m	-NOK 190m
Sep 30 2023	n/a	n/a	-NOK 226m
Jun 30 2023	n/a	n/a	-NOK 258m
Mar 31 2023	n/a	n/a	-NOK 293m
Dec 31 2022	NOK 11m	NOK 5m	-NOK 302m
Sep 30 2022	n/a	n/a	-NOK 294m
Jun 30 2022	n/a	n/a	-NOK 304m
Mar 31 2022	n/a	n/a	-NOK 309m
Dec 31 2021	NOK 4m	NOK 1m	-NOK 309m

Rémunération vs marché: La rémunération totale de Martin ($USD 969.36K ) est supérieure à la moyenne des entreprises de taille similaire sur le marché UK ($USD 369.30K ).

Rémunération et revenus: La rémunération de Martin a été cohérente avec les performances de l'entreprise au cours de l'année écoulée.

PDG

Martin Olin (55 yo)

3.1yrs

Titularisation

NOK 10,231,670

Compensation

Mr. Martin Olin serves as Chief Executive Officer at BerGenBio ASA since September 8, 2021. Mr. Olin has been Chairman of the Board at AcouSort AB (publ) since April 28, 2021. He has experience from execut...

Équipe de direction

Nom	Position	Titularisation	Compensation	Propriété
Martin Olin	Chief Executive Officer	3.1yrs	NOK 10.23m	0.078% NOK 262.4k
Rune Skeie	Chief Financial Officer	6.6yrs	NOK 3.59m	0.010% NOK 33.6k
Cristina Oliva	Chief Medical Officer	2.5yrs	NOK 5.70m	pas de données
Graham Morell	Head of IR	no data	pas de données	pas de données
Gayle Mills	Chief Business Officer	2.9yrs	NOK 3.39m	pas de données
Akil Jackson	Medical Director	no data	pas de données	pas de données

3.0yrs

Durée moyenne de l'emploi

55yo

Âge moyen

Gestion expérimentée: L'équipe de direction de 0RU5 est considérée comme expérimentée (ancienneté moyenne 2.8 ans).

Membres du conseil d'administration

Nom	Position	Titularisation	Compensation	Propriété
Sally Bennett	Independent Non-Executive Director	3.8yrs	NOK 358.00k	0.012% NOK 40.8k
John Heymach	Member of Scientific Advisory Board	1.7yrs	pas de données	pas de données
Shu Kam Mok	Member of Scientific Advisory Board	1.7yrs	pas de données	pas de données
Debra Barker	Independent Non-Executive Director	5.6yrs	NOK 344.00k	0.012% NOK 40.3k
Anders Tullgren	Independent Chairman of the Board	2.8yrs	NOK 848.00k	0.055% NOK 187.0k
Enriqueta Font	Member of Scientific Advisory Board	1.7yrs	pas de données	pas de données
Solange Peters	Member Scientific Advisory Board	1.7yrs	pas de données	pas de données

1.7yrs

Durée moyenne de l'emploi

61yo

Âge moyen

Conseil d'administration expérimenté: Les membres du conseil d'administration de 0RU5 ne sont pas considérés comme expérimentés (ancienneté moyenne 1.5 ans), ce qui suggère un nouveau conseil d'administration.

BerGenBio Gestion

Gestion contrôle des critères 2/4

Informations clés

Mises à jour récentes de la gestion

Martin Olin to Step Down from BerGenBio ASA as CEO

High number of new and inexperienced directors

High number of new and inexperienced directors

High number of new and inexperienced directors

High number of new and inexperienced directors

BerGenBio ASA Announces Resignation of Francois Thomas from the Board of Directors

Recent updates

Martin Olin to Step Down from BerGenBio ASA as CEO

BerGenBio ASA Announces Safety Data from Dose Escalation Phase 1b in First Line NSCLC Patients

High number of new and inexperienced directors

New major risk - Market cap size

High number of new and inexperienced directors

High number of new and inexperienced directors

New major risk - Financial position

BerGenBio ASA Announces Closure of EU-Solidact Bemcentinib Study Arm in Hospitalized COVID-19 Patients

BerGenBio ASA Announces Final Bemcentinib Phase 2 Data in AML and MDS Presented at the 2023 ASH Meeting

BerGenBio ASA has completed a Follow-on Equity Offering in the amount of €240.87 million.

New major risk - Financial position

BerGenBio ASA to Report Q4, 2024 Results on Feb 19, 2025

BerGenBio ASA Announces Full Results of its Phase 2 BGBC008 Study of Bemcentinib and Pembrolizumab in Second Line Non-Small Cell Lung Cancer

New major risk - Shareholder dilution

BerGenBio ASA has completed a Follow-on Equity Offering in the amount of NOK 250 million.

High number of new and inexperienced directors

BerGenBio Announces Data from Bemcentinib Trial in Mesothelioma Presented at ASCO

BerGenBio ASA Announces Resignation of Francois Thomas from the Board of Directors

BerGenBio ASA to Report Q1, 2023 Results on Jun 22, 2023

High number of new and inexperienced directors

High number of new and inexperienced directors

BerGenBio ASA Announces Positive Data From Phase 2 Trial of Bemcentinib in Combination with Pembrolizumab in 2L+ NSCLC Patients

BerGenBio ASA Announces Board Appointments

BerGenBio ASA to Report Q3, 2023 Results on Nov 14, 2023

BerGenBio ASA Announces Initiation of Phase 1b/2a Trial Evaluating Bemcentinib in 1st line Non-Small Cell Lung Cancer Patients Harboring STK11 Mutations

BerGenBio ASA Announces First Patient Randomized in Bemcentinib Trial in Eu-Solidact Platform for Hospitalized Covid-19 Patients

BerGenBio ASA Provides Update on Clinical Development

Chairman of the Board recently bought kr268k worth of stock

BerGenBio ASA Announces Complete Data Analysis of Accord2 Phase II Bemcentinib Study in Hospitalized Covid-19 Patients - Primary Efficacy Endpoint Met

Bergenbio Presents Bemcentinib Covid-19 Clinical Trial Data At Eccmid 2022

BerGenBio ASA Appoints Cristina Oliva as Chief Medical Officer, Effective April 25, 2022

High number of new and inexperienced directors

Chief Executive Officer recently bought kr204k worth of stock

BerGenBio ASA Completes Recruitment of Phase II AML Study ((BGBC003)

Chief Executive Officer Richard Godfrey has left the company

BerGenBio ASA Presents Encouraging Combined Data for Bemcentinib from Two Phase II Covid-19 Studies At Eccmid

BerGenBio ASA Updates Preliminary Survival Data from the Ongoing Phase II Study of Bemcentinib

BerGenBio ASA Receives Food and Drug Administration Fast Track Designation for Bemcentinib / Anti-Pd-(L)1 Combination in NSCLC

BerGenBio ASAPresents Data from Phase I/II Bemcentinib/Erlotinib Combination Trial in NSCLC

BerGenBio ASA to Present Data from Phase I/II Bemcentinib/Erlotinib Combination Trial in NSCLC at ASCO Meeting

BerGenBio ASA Announces Top Line Data from Phase II Trial Assessing Bemcentinib in Hospitalised Covid-19 Patients

BerGenBio ASA Announces Pre-Clinical COVID-19 Data Presented at Virtual Immunology 2021

BerGenBio ASA Completes Enrolment into Latest Cohort of Phase II Bemcentinib Combination Study in Refractory NSCLC

BerGenBio ASA Announces Start of Phase 1B Trial of Anti-AXL Antibody Tilvestamab (BGB149)

BerGenBio ASA Closes Recruitment into Trial Assessing Bemcentinib in Covid-19 Patients

BerGenBio ASA Announces Second Data Monitoring Committee Recommends Continuation of Bergenbio's BGBC020 Trial Assessing Bemcentinib in COVID-19 Patients

BerGenBio ASA Presents an Update from Its Phase II Study of Bemcentinib in Combination with Anti-PD-1 Therapy Pembrolizumab (Bgbc008)

Bergenbio to Present Updates from Ongoing Phase II Bemcentinib Combination Study in Refractory NSCLC At WCLC 2020

BerGenBio ASA to Report Q4, 2020 Results on Feb 10, 2021

BerGenBio ASA to Report Q3, 2021 Results on Nov 16, 2021

BerGenBio ASA Presents Updated Clinical Data from Two Phase II Studies of Bemcentinib in AML and MDS Patients at ASH 2020

BerGenBio ASA Confirms First Patient Enrolled in Phase II Trial Assessing Bemcentinib as Potential Treatment for COVID-19 in India

Revenue in line with expectations

BerGenBio ASA Presents Phase II Bemcentinib Combination Study in NSCLC At Annual SITC Meeting

BerGenBio ASA to Present Clinical Translational Data from the Ongoing Phase II Bemcentinib Combination Study in NSCLC At Annual SITC Meeting

BerGenBio Presents Data on Anti-Axl Antibody Tilvestamab

BerGenBio Announces First Patient Dosed with Bemcentinib in Relapsed Malignant Pleural Mesothelioma Investigator Sponsored Phase IIa Study

Bergenbio ASA Receives Regulatory Approval from the India Regulatory Authority to Proceed with Phase II Clinical Trial to Assess the Efficacy and Safety of Bemcentinib

BerGenBio ASA Receives Approval from Norwegian Regional Ethics Committee for COVID-19 South Africa Trial

BerGenBio ASA to Report Q2, 2020 Results on Aug 18, 2020

First half earnings released

Analyse de la rémunération des PDG

PDG

Titularisation

Compensation

Équipe de direction

Durée moyenne de l'emploi

Âge moyen

Membres du conseil d'administration